Scaling up Biologics Production at Mabion with Single-use Bioreactors and Automated Monitoring
- Scaling up biologics production at Mabion utilizes single-use bioreactors. We implement a scale-out strategy by adding parallel units instead of larger tanks, allowing for rapid capacity expansion that maintains a consistent cell culture environment optimized during process development.
- Our approach is further supported by automated monitoring and real-time sensors that provide the data-driven process control necessary to maintain product quality and comparability throughout the manufacturing lifecycle.
Scaling Up Biologics Production from Process Development to GMP Manufacturing
Imagine a world where life-saving medicine is brewed not in massive steel cathedrals, but in agile, high-tech systems that adapt as quickly as a virus mutates. This is the heartbeat of modern biologics manufacturing, where the transition from a lab bench to global distribution is no longer a decades-long crawl.
The journey of a biologic begins in a tiny vial, but its ultimate destination is a patient in need, requiring a massive leap in volume. This bioprocess scale-up is a critical test where the efficiency optimized at a small scale must be perfectly replicated in a larger environment. Historically, this meant moving from small glass flasks to massive stainless steel tanks, often introducing unpredictable changes in cell behavior.
During early biologics process development, R&D team use miniaturized, high-throughput systems like 15 mL or 250 mL bioreactors to screen thousands of variables. These lab-scale successes provide the blueprint, but translating that performance to a 2,000 L vessel requires deep engineering insights. The goal is to move through these scales with confidence, ensuring that the final drug is identical to the one that worked in the lab.1
The transition to GMP biologics manufacturing is where the stakes reach their highest point, as every batch must meet stringent regulatory safety standards. At this stage, manufacturers often utilize pilot-scale engineering runs to identify scale-sensitive variables before the final validation batches are initiated. This bridge between development and production is essential for maintaining product consistency.
To streamline this path, modern facilities are adopting platform consistency, where the equipment geometry remains similar across all volumes. This approach reduces the need for repeated process re-tuning, allowing for a faster progression from concept to clinic. Successful scaling up biologics production is about managing complexity through strategic design and disciplined execution.2
Single-Use Bioreactors in Modern Biologics Production Strategies
For decades, the industry was dominated by stainless steel bioreactors – massive systems requiring months of cleaning validation and millions in investment. The emergence of single-use bioreactors changed the narrative, replacing these permanent structures with flexible, disposable polymer bags. This shift allows for faster facility deployment and a significantly lower capital risk for biotech developers.
The magic of single-use technology biologics lies in its ability to eliminate the laborious Clean-in-Place (CIP) and Steam-in-Place (SIP) cycles. By discarding the pre-sterilized bag after each run, operators virtually eliminate the risk of cross-contamination between different drug products. This efficiency enables facilities to pivot between different therapies in hours rather than days.3
In the quest for biologics production scalability, many companies are now scaling out by adding parallel units instead of building bigger tanks. While traditional scaling stops at around 2,000 L for single-use systems due to physical weight limits, running multiple units in parallel can match the output of much larger vessels. This strategy provides a safeguard. If one unit fails, the others in the production run are still viable.
Furthermore, these modular systems support scaling up biologics production as part of a global manufacturing strategy, where identical production nodes can be set up anywhere in the world. This flexibility is vital for responding to unpredictable market demands or sudden healthcare crises like a pandemic.
Critical Parameters Influencing Biologics Scale-Up Performance
When we grow cells at a large scale, the physical environment inside the tank becomes a complex dance of transport phenomena. To ensure a successful bioprocess scale-up, engineers must maintain several scale-dependent parameters within precise windows. The objective is to reproduce the cells’ growth environment, ensuring they receive the same nutrients and oxygen they had in the lab.
One of the most vital metrics is the oxygen mass transfer coefficient (kLa), which describes how efficiently a system can breathe life into a dense cell culture. As the vessel volume grows, the surface area to volume ratio decreases, making it harder to strip away waste gases like carbon dioxide. Maintaining a constant kLa across scales ensures that oxygen delivery does not become the rate-limiting factor for production.4
While it is impossible to keep every parameter perfectly constant when volume increases, engineers identify an overlap zone where these critical values align. When scaling up biologics production, finding this balanced operating window is what separates a successful commercial harvest from a costly batch failure.
Automated Monitoring and Data-Driven Process Control in Biologics Manufacturing
In the high-stakes world of biologics manufacturing, flying blind is never an option, which is why we rely on automated monitoring biologics. Real-time sensors act as the eyes and ears inside a bioreactor, tracking variables with high precision. This constant stream of data allows for a level of process control.
Sophisticated process monitoring biologics technologies, such as Raman spectroscopy, allow us to see through the cell culture broth to measure metabolites and product titers instantly. These sensors can provide real-time insights, enabling immediate adjustments to nutrient feeding strategies. By catching deviations early, we can prevent small errors from cascading into catastrophic losses.5
Integrating Single-Use Technologies with GMP Biologics Manufacturing
Modern GMP biologics manufacturing facilities are increasingly modular, using self-contained cleanroom units that can be rapidly expanded as demand grows. Cleanroom designs allow for parallel production lines to operate in the same space, significantly increasing a facility’s total throughput. The disposable nature of the equipment means that the facility layout can be reconfigured for a new product with minimal disruption. This gives a CDMO a huge advantage over an innovator seeking clinical or commercial scale production.5
Effective integration also means aligning single-use systems with existing downstream purification steps like chromatography and filtration. By using single-use membrane technologies instead of traditional resin columns, manufacturers can match the high output of modern bioreactors. This holistic approach ensures that no section of the production line becomes a bottleneck for the entire process.
Finally, successful GMP integration depends on robust supplier qualification and lifecycle management of all disposable components. Reliable partners must provide materials that remain consistent from one manufacturing campaign to the next. Implementing single-use technology biologics within a GMP framework requires a rigorous focus on supply chain integrity.
How Mabion Supports Scalable and Consistent Biologics Production?
Companies like Mabion thrive in this new era by focusing on upstream development biologics that prioritize both efficiency and high product quality. By leveraging steadfast cell lines, CDMO can achieve high titers that once required tanks ten times larger. This intensity allows for more drug to be produced in a smaller footprint, reducing the overall cost of goods.
As the industry moves toward end-to-end manufacturing, the role of a flexible partner becomes even more essential. As a biologics CDMO, Mabion provides a path to the clinic that is both faster and lower in risk. The heartbeat of our operation is its biologics production scalability, which allows for a smooth transition from early clinical trials to late-stage commercialization. In the rapidly evolving landscape of biotechnology, this marriage of single-use flexibility and automated precision is the definitive way forward.
FAQ
Prepared by:
Marketing Specialist
References
- National Institutes of Health. Manufacturing Scale-Up of Drugs and Biologics. U.S. Department of Health and Human Services. 2024.
- Knurek J. Bioprocess Scale-Up from Lab Scale to Commercial GMP Manufacturing. Mabion Science Hub. 2026.
- Williams J. Beyond Automation: Improving Efficiency, Sustainability and Reliability Using Clean-in-Place and Steam-in-Place In-Depth Analytics. BioPharma APAC. 2023.
- Seidel S, Maschke RW, Werner S, Jossen V, Eibl D. Oxygen Mass Transfer in Biopharmaceutical Processes: Numerical and Experimental Approaches. Chemie Ingenieur Technik, 2021; 93: 42-61.
- Powierża K. Microbiological Cleaning in Cleanrooms in CDMO Operation. Mabion Science Hub. 2025.
